Summary
Cencora, Inc. (COR) announced a significant leadership transition with the appointment of Eva C. Boratto as Executive Vice President and Chief Financial Officer, effective June 29, 2026. Ms. Boratto brings extensive financial leadership experience, including previous CFO roles at Bath & Body Works and significant tenures at CVS Health and Merck & Co. She also serves on the boards of Mars, Inc. and United Parcel Service, Inc., both as Chair of the Audit Committee, bringing valuable corporate governance experience to Cencora. This appointment coincides with the retirement of current CFO James F. Cleary, who will remain in an advisory capacity through the end of 2026. The company also reaffirmed its fiscal year 2026 adjusted diluted earnings per share guidance of $17.70 to $17.90, along with long-term guidance for adjusted operating income growth of 7% to 10% and adjusted diluted earnings per share growth of 10% to 14%. This filing provides details on Ms. Boratto's compensation package, including a substantial sign-on bonus and restricted stock units, as well as reaffirmation of financial outlook, signaling stability and continued strategic focus.
Key Highlights
- 1Eva C. Boratto appointed as new Executive Vice President and Chief Financial Officer, effective June 29, 2026.
- 2James F. Cleary to retire as CFO but will serve in an advisory role until the end of 2026.
- 3Ms. Boratto possesses extensive experience from prior CFO roles at Bath & Body Works and significant financial leadership positions at CVS Health and Merck & Co.
- 4Ms. Boratto's compensation includes an annual base salary of $1,000,000, an annual bonus target of 100% of base salary, and eligibility for long-term and short-term incentives.
- 5A one-time sign-on bonus of $2,000,000 and a $6,000,000 restricted stock unit award (subject to three-year vesting) have been granted to Ms. Boratto.
- 6Cencora reaffirms its fiscal year 2026 adjusted diluted EPS guidance of $17.70 to $17.90.
- 7Long-term financial guidance remains unchanged, with projected adjusted operating income growth of 7% to 10% and adjusted diluted EPS growth of 10% to 14%.